Please use this identifier to cite or link to this item:
Title: Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
Author: Olloquequi, Jordi
Cano Fernández, Amanda
Sánchez López, E. (Elena)
Carrasco, Marina (Carrasco Pérez)
Verdaguer Cardona, Ester
Fortuna, Ana
Folch, Jaume
Bulló, Mònica
Auladell i Costa, M. Carme
Camins Espuny, Antoni
Ettcheto Arriola, Miren
Keywords: Malaltia d'Alzheimer
Malalties neurodegeneratives
Alzheimer's disease
Neurodegenerative Diseases
Issue Date: 19-Sep-2022
Publisher: Elsevier Masson SAS
Abstract: Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct negative regulator of several receptor and receptor-associated tyrosine kinases. This widely localized enzyme has been involved in the pathophysiology of several diseases. More recently, PTP1B has attracted attention in the field of neuroscience, since its activation in brain cells can lead to schizophrenia-like behaviour deficits, anxiety-like effects, neurodegeneration, neuroinflammation and depression. Conversely, PTP1B inhibition has been shown to prevent microglial activation, thus exerting a potent anti-inflammatory effect and has also shown potential to increase the cognitive process through the stimulation of hippocampal insulin, leptin and BDNF/TrkB receptors. Notwithstanding, most research on the clinical efficacy of targeting PTP1B has been developed in the field of obesity and type 2 diabetes mellitus (TD2M). However, despite the link existing between these metabolic alterations and neurodegeneration, no clinical trials assessing the neurological advantages of PTP1B inhibition have been performed yet. Preclinical studies, though, have provided strong evidence that targeting PTP1B could allow to reach different pathophysiological mechanisms at once. herefore, specific interventions or trials should be designed to modulate PTP1B activity in brain, since it is a promising strategy to decelerate or prevent neurodegeneration in aged individuals, among other neurological diseases. The present paper fails to include all neurological conditions in which PTP1B could have a role; instead, it focuses on those which have been related to metabolic alterations and neurodegenerative processes. Moreover, only preclinical data is discussed, since clinical studies on the potential of PTP1B inhibition for treating neurological diseases are still required. Keywords: Alzheimer's disease; Insulin receptor; Neurodegenerative diseases; Neuroinflammation; Neurological disorders; PTP1B; Type 2 diabetes.
Note: Reproducció del document publicat a:
It is part of: Biomedicine & Pharmacotherapy, 2022
Related resource:
ISSN: 0753-3322
Appears in Collections:Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Bioquímica i Fisiologia)

Files in This Item:
File Description SizeFormat 
724998.pdf2.23 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons